Valuation : Damora Therapeutics, Inc.

Market Cap 165.7Cr 142.89Cr 135.23Cr 122.5Cr 229.81Cr 16TCr 231.16Cr 1.61TCr 616.96Cr 8.05TCr 622.28Cr 608.54Cr 25TCr P/E 2026 *
-14x
P/E 2027 * -13.6x
Enterprise Value 119.54Cr 103.09Cr 98Cr 88Cr 165.79Cr 11TCr 166.77Cr 1.16TCr 445.1Cr 5.8TCr 448.94Cr 439.03Cr 18TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.4%
Yield 2026 *
-
Yield 2027 * -
1 day+4.69%
1 week+0.36%
Current month-0.28%
1 month-4.87%
3 months+39.45%
6 months+10.15%
Current year+22.12%
1 week 25.63
Extreme 25.63
30.74
1 month 25.63
Extreme 25.63
33.56
Current year 16.5
Extreme 16.5001
34.89
1 year 2.53
Extreme 2.53
38.33
3 years 2.01
Extreme 2.01
38.33
5 years 2.01
Extreme 2.01
112.5
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 30/03/2026
Director of Finance/CFO - 01/05/2026
Chief Tech/Sci/R&D Officer 60 05/01/2026
Director TitleAgeSince
Chairman 40 23/03/2026
Director/Board Member 42 10/11/2025
Director/Board Member 41 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
12/08/26 Free

Director

30,350 0.0493%
06/07/26 Sell

General Counsel

-245 0.0004%
01/05/26 Other

Chief Financial Officer

3,12,535 0.5077%
Change 5-day change 1-year change 3-year change Capi.($)
+4.69%+0.36%+842.95%+100.00% 165.7Cr
-0.71%-8.73%-4.56%+9.80% 4.61TCr
+0.21%-3.37%+403.76%+534.40% 4.36TCr
+1.74%-3.63%+42.37%+22.59% 4.24TCr
+1.38%-4.46%+10.38%+79.88% 3.89TCr
-1.44%-4.76%+10.26%+38.52% 3.22TCr
+0.87%-2.81% - - 1.72TCr
+0.75%-0.99%+23.25%+116.71% 1.63TCr
-0.31%-3.76%+12.33%+30.49% 1.43TCr
+1.93%-5.14%+81.55%+39.31% 1.3TCr
Average +0.91%-4.69%+158.03%+107.97% 2.66TCr
Weighted average by Cap. +0.43%-5.09%+92.32%+129.08%

Financials

2026 *2027 *
Net sales - -
Net income -13Cr -11Cr -10Cr -9.27Cr -17Cr -1.2TCr -17Cr -121.51Cr -47Cr -608.92Cr -47Cr -46Cr -1.93TCr -15Cr -13Cr -12Cr -11Cr -21Cr -1.43TCr -21Cr -145.48Cr -56Cr -729.05Cr -56Cr -55Cr -2.31TCr
Net Debt -46Cr -40Cr -38Cr -34Cr -64Cr -4.41TCr -64Cr -447.2Cr -171.86Cr -2.24TCr -173.34Cr -169.51Cr -7.09TCr -35Cr -30Cr -29Cr -26Cr -49Cr -3.36TCr -49Cr -340.84Cr -130.98Cr -1.71TCr -132.11Cr -129.19Cr -5.4TCr
Logo Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.
Employees
7
Date Price Change Volume
11/26/11 $28.09 +4.66% 5,25,326
10/26/10 $26.84 +2.17% 6,39,787
09/26/09 $26.27 -9.94% 5,00,073
08/26/08 $29.17 -2.96% 5,59,967
04/26/04 $30.06 +7.36% 2,95,832
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
28.09USD
Average target price
44.67USD
Spread / Average Target
+59.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!